Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial
Deepak Cyril D’Souza(Yale University), Patrick D. Skosnik(Connecticut Mental Health Center), Peter Morgan(Yale University), Emma Deaso(Yale University), Mohini Ranganathan(Yale University), Kim Bielen(Yale University), Rajiv Radhakrishnan(JSS Medical College and Hospital), John D. Cahill(Yale University), Jose Cortes-Briones(VA Connecticut Healthcare System), Grai Bluez(Yale University), Gina Creatura(Temple University), Toral Surti(Yale University), Swapnil Gupta(Yale University), Mohamed Sherif(Yale University), Alexandros Makriyannis(Northeastern University), Aarti Gupta(Yale University), Halle Thurnauer(Yale University)
Cited by 194
Related Papers
A new antibiotic selectively kills Gram-negative pathogens
|Nature|2019|744
The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial
|Psychopharmacology|2018|235
Rapid Changes in Cannabinoid 1 Receptor Availability in Cannabis-Dependent Male Subjects After Abstinence From Cannabis
|Biological Psychiatry Cognitive Neuroscience and Neuroimaging|2015|210